Lipopolysaccharide Pretreatment Protects from Renal Ischemia/Reperfusion Injury

Possible Connection to an Interleukin-6-Dependent Pathway

Uwe Heemann,* Attila Szabo,*[†] Peter Hamar,*[†]
Veronika Müller,*[†] Oliver Witzke,* Jens Lutz,* and
Thomas Philipp*

From the Department of Nephrology,* University of Essen, Essen,
Germany; and the Semmelweis Medical University,[†] Budapest,
Hungary

In vivo administration of low doses of lipopolysaccharide (LPS) to rodents can protect these animals from subsequently administered, usually lethal doses of endotoxin or LPS. In this study we tested the effects of LPS pretreatment on ischemia/reperfusion injury in the kidney. Male C57/B1 mice were pretreated with different doses of LPS or phosphate-buffered saline on days -4 and -3. The right kidney was removed, and the vessels of the left kidney were clamped for 30 or 45 minutes on day 0. Creatinine levels and survival of animals were monitored. To test the involvement of cytokines, additional animals were harvested before ("time 0") and 15 minutes, 1, 2, 8, and 16 hours after reperfusion for histology, immunohistochemistry, terminal deoxynucleotidyltransferase-mediated UTP end-labeling assay, and reverse transcriptase-polymerase chain reaction analysis (including tumor necrosis factor (TNF)- α , interleukin (IL)-1, IL-6, inducible nitric oxide synthase (iNOS), and interferon (IFN)- γ messenger RNA (mRNA)). In controls, renal ischemia of 30 minutes was nonlethal, whereas 73% of the animals died within 48 ± 18 hours, after 45 minutes of ischemia. All different doses of LPS protected the animals from lethal renal ischemia/reperfusion injury. Starting at similar levels, serum creatinine increased significantly in controls but not in LPS-pretreated animals over time. As early as 2 hours after reperfusion, tubular cell damage was significantly more pronounced in controls than in LPS-treated mice. In controls, tubules deteriorated progressively until 8 hours of reperfusion. At this time, more than 50% of tubular cells were destroyed. This destruction was accompanied by a pronounced leukocytic infiltration, predominantly by macrophages. In contrast, LPS pretreatment prevented the destruction of kidney tissue and infiltration by leukocytes. The terminal de-

oxynucleotidyltransferase-mediated UTP end-labeling assay revealed significantly more apoptotic cells in controls compared with LPS-pretreated animals. IL-1, IFN- γ , and iNOS mRNA expression did not differ between the groups throughout the time points examined. However, the expression of TNF- α mRNA was significantly increased at 2 hours and IL-6 mRNA was significantly down-regulated before ischemia and shortly after reperfusion in the LPS-pretreated kidneys. Therefore, we found that sublethal doses of LPS induced cross-tolerance to renal ischemia/reperfusion injury. Our data suggest that increased TNF- α and reduced IL-6 mRNA expression might be responsible. However, more studies are needed to decipher the exact mechanism. (Am J Pathol 2000, 156:287-293)

Ischemia and reperfusion result in tissue injury in a number of organs, including heart,¹ brain,² kidney,³ and gastrointestinal tract,⁴ with important implications for patient morbidity and mortality. The treatment of acute renal failure is cost intensive and requires hospitalization. Even today, ischemia-induced acute renal failure is associated with a mortality rate of $\approx 50\%$.⁵ The pathophysiological mechanisms leading to acute ischemic renal failure are not completely understood. There is no clinically effective therapy that prevents ischemic injury completely.⁶ Moreover, this so called ischemia/reperfusion injury contributes to renal damage in transplantation,⁷ revascularization procedures, and periods of hypoperfusion.⁸

Severe reduction of renal blood flow causes cell damage by high-energy phosphate depletion and the subsequent failure to maintain physiological ion gradients across the cellular membrane. The severity of the injury depends on the duration of ischemia and the availability of collateral perfusion, although, paradoxically, the restoration of blood flow itself is associated with further tissue damage. Reperfusion with oxygenated blood is associated with the generation of free radicals and thus lipid peroxidation, polysaccharide depolymerization, and desoxyribonucleotide degradation. Injured endothelial cells

Accepted for publication September 4, 1999.

Address reprint requests to Uwe Heemann M.D., University Essen, NTP-Ambulanz, Hufelandstr. 55, 45122 Essen, Germany. E-mail: uwe.heemann@uni-essen.de.

Table 1. Protocols for LPS Administration

Time (day)	Protocols					
	Protocol 1		Protocol 2		Protocol 3	
	Controls	LPS	Controls	LPS	Controls	LPS
−4	10 mg/kg vehicle	10 mg/kg LPS	4 mg/kg vehicle	4 mg/kg LPS	2 mg/kg vehicle	2 mg/kg LPS
−3	50 mg/kg vehicle	50 mg/kg LPS	16 mg/kg vehicle	16 mg/kg LPS	10 mg/kg vehicle	10 mg/kg LPS
0	Ischemia	Ischemia	Ischemia	Ischemia	Ischemia	Ischemia

fail to initiate the relaxation of vascular smooth muscle cells, release potent vasoconstrictors, and swell; the permeability is increased, and finally, leukocytes and platelets are trapped and accumulate in the microcirculation and the tissue. Eventually this results in a progressive loss of perfusion and further tissue damage.^{7,8}

Both sepsis and endotoxemia are generally regarded as destructive processes.^{9–12} Preconditioning with endotoxin results in adaptation or tolerance, which is characterized by a reduced systemic response to a subsequent challenge with a large dose of homologous or heterologous endotoxin.^{9–12} Although endotoxin has been used to induce resistance against a subsequent identical insult,¹³ it has also been demonstrated that endotoxin provokes cross-tolerance against other forms of injury. Some authors reported endotoxin-derived protection against ischemia/reperfusion injury in myocardium¹⁴ and liver.¹⁵

In this study, we established a new model for endotoxin-induced cross-tolerance to renal ischemia/reperfusion injury. To gain some insights into the underlying processes, we evaluated cellular infiltration and cytokine production in a second set of experiments.

Materials and Methods

Animals

Male CD57/BI mice (weight, 20–30 g) were used as experimental animals, maintained on a standard diet, and given water *ad libitum*. The animal protocol was reviewed and approved by a governmental animal care and research committee.

Experimental Design and Operation

Operative procedures were performed under general anesthesia induced by 5.3 mg/100 g nembutal and 0.02 mg/100 g atropin-sulfate administrated intraperitoneally. After a midline laparotomy incision, renal artery and vein of the left kidney were isolated and occluded with a clamp. After ischemia, the clamp was withdrawn, the right kidney was removed, the laparotomy incision was closed, and the animals were allowed to wake up.

In the first step, lethal renal ischemic time was determined in the mice. Two different times of ischemia were examined: 30 minutes and 45 minutes ($n = 26/\text{group}$).

In the second step, we established a model for endotoxin-induced cross-tolerance to lethal renal ischemia/reperfusion injury. Animals were treated according to three different protocols for lipopolysaccharide (LPS) ad-

ministration (*Escherichia coli*, serotype 0111:B4; Sigma Chemical Co., St. Louis, MO) (Table 1) ($n = 12/\text{group}$).

In the third step, one group of animals was treated with 2 mg/kg LPS on day −4, and 10 mg/kg LPS on day −3, whereas the other animals received vehicle (0.9% NaCl) and served as controls. To determine the role of several cytokines, animals were narcotized and bled, and the kidneys were removed and stored in 4% buffered formalin or liquid nitrogen before ischemia (time 0) or 15 minutes, 1, 2, 8, and 16 hours after reperfusion ($n = \text{eight}/\text{group/time point}$).

Functional Parameters

Serum creatinine concentrations were determined photometrically with a commercially available test kit (Boehringer Ingelheim, Ingelheim, Germany).

Histological Analysis

Paraffin sections of kidneys fixed in 4% neutral buffered formalin were stained with hematoxylin and eosin and periodic acid-Schiff reagent. Samples were coded and examined in a blinded fashion. Tubular damage and leukocyte infiltration were semiquantitatively evaluated on a scale from 0 to 3 (0 = none, 1 = mild, 2 = moderate, 3 = severe). Additionally, neutrophils were manually counted as cells per field of view at $\times 400$ magnification.

Immunohistological Analysis

Fresh frozen sections were stained with antibodies against lymphocytes (CD4 and RM45, Pharmingen, San Diego, CA) and macrophages (CD11b, M1/70, Pharmingen) to establish the involvement lymphocytes. Furthermore, we evaluated apoptosis with the TUNEL assay based on the description of the manufacturer (Boehringer Mannheim, Mannheim, Germany).

Positively stained cells were counted at $\times 400$ magnification and described as cells per field of view.

Reverse Transcriptase-Polymerase Chain Reaction

Total RNA Isolation

Total RNA was extracted and used for reverse transcriptase-polymerase chain reaction (RT-PCR). A part of the kidney was stored in 500 μl of cold lysis solution,

containing 4 mol/L guanidine isothiocyanate (Sigma), 25 mmol/L sodium citrate (pH 7.0), 0.1 mol/L β -mercaptoethanol, and 0.5% sarcosyl, and frozen in liquid nitrogen. Total RNA was extracted by the modified guanidine-isothiocyanate preparation method.¹⁶ Briefly described, frozen tissues were mixed with 4 ml guanidine isothiocyanate buffer (4 mol/L guanidine isothiocyanate; Sigma) and acid phenol-chloroform (pH 4; Sigma), and homogenized. The samples were centrifuged at 1500 g for 10 minutes at 20°C. The supernatant was treated with an equal volume of isopropanol. The mixture was centrifuged, and the RNA was washed with RNeasy Total RNA Isolations Kit (Qiagen GmbH, Germany) and stored at -80°C until further processing. RNA concentration was measured spectrophotometrically.

Reverse Transcription

RNA was amplified by reverse transcription (RT) with an oligo(dT)₁₂₋₁₈ primer (Life Technologies, Inc., Grand Island, NY). Total RNA (1 μ g) was added to 0.5 μ g of primer. A reaction mixture was added containing buffer solution (50 mmol/L Tris-hydrochloride buffer, pH 8.3, 75 mmol/L potassium chloride, 5 mmol/L magnesium dichloride, 5 mmol/L dithiothreitol; Life Technologies, Inc.); 1 mmol/L each of adenosine triphosphate, thymidine triphosphate, guanosine triphosphate, and cytosine triphosphate (deoxynucleoside triphosphates from Boehringer Mannheim GmbH); 40 U/ μ l of recombinant ribonuclease inhibitor (Promega), and 0.5 μ l of 200-U/ μ l Maloney-murine leukemia virus reverse transcriptase (Life Technologies), and the first chain reaction was allowed to proceed (36°C, 1 h). The reaction was halted by heating to 95°C for 5 minutes followed by cooling on ice.

Amplification of Specific Complementary DNA

Specific complementary-DNA products corresponding to mRNA for TNF- α , IFN- γ , IL-1, IL-6, inducible nitric oxide synthase (iNOS), and β -actin¹⁷ were amplified by PCR. A 1- μ l sample was taken from the RT reaction for PCR, which was performed in PCR buffer (750 mmol/L Tris-hydrochloride, pH 9.0, 200 mmol/L (NH₄)₂SO₄, 0.1% (w/v) Tween, 20 mmol/L magnesium dichloride; Dianova, Hamburg, Germany), using 0.2 mmol/L of each deoxynucleoside triphosphate, 1 μ mol/L of both primers (Eurogentec, Belgium), and 2.5 U *Thermus aquaticus* (Taq) DNA polymerase (Dianova). A Perkin-Elmer Thermal Cycler (Model 2400, Perkin-Elmer, Norwalk, CT) was used for amplification with the following sequence profile: initial denaturation at 94°C for 3 minutes followed by 30–40 cycles of three-temperature PCR (denaturing, 94°C for 30 seconds; annealing, 55°C for 30 seconds; extension, 72°C for 30 seconds) and ending with a final extension at 72°C for 7 minutes and cooling to 4°C.

Gel Electrophoresis

The amplified PCR product was identified by electrophoresis of 10- μ l sample aliquots on 1.5% agarose gel

Figure 1. Effect of LPS pretreatment on survival after 45 minutes of lethal renal ischemia.

stained with 0.5 μ g/ml of ethidium bromide. The sample products were visualized by UV transillumination, and the gel was photographed. Specific products were identified by size in relation to a known 1-kb oligonucleotide DNA ladder (Life Technologies) run with each gel. Cytokine complementary DNA was semiquantitated by densitometric comparison with β -actin (internal control) from the same sample after the positive image was digitized by video for computerized densitometry. The results are given as the ratio of intensity of cytokines and β -actin mRNA $\pm$ SEM.

Statistical Analysis

Data were expressed as mean $\pm$ SEM. Parametric data were compared using Student's *t*-test. Nonparametric data were tested using Mann-Whitney analysis of ranks. *P* < 0.05 was accepted as statistically significant.

Results

Survival after Different Times of Ischemia

After 30 minutes of renal ischemia, all animals (*n* = 26) survived until the end of the follow-up (15 days). After 45 minutes of renal ischemia (*n* = 21), 20 animals died after 48 $\pm$ 24 hours (74%). One animal survived for 13 days (Figure 1).

Effect of Pretreatment with LPS on Ischemia/Reperfusion Injury

After pretreatment with LPS, all animals (*n* = 35) survived for more than 50 days, independent of the administration protocol. Therefore, 45 minutes of ischemia was chosen for the following experiments.

Whereas the body weight of vehicle-treated animals remained constant during the period observed, it decreased in LPS-treated mice after the first administration by approximately 10% and recovered thereafter.

Serum creatinine was similar before and 15 minutes after perfusion in both groups (controls: 1.2 $\pm$ 0.06 and 0.76 $\pm$ 0.07; *versus* LPS: 0.94 $\pm$ 0.11 and 0.65 $\pm$ 0.06 mg/dl). One hour after ischemia, creatinine had in-

Figure 2. Effect of LPS pretreatment on serum creatinine before ischemia ("0") and 15 minutes, 1, 2, 8, and 16 hours after reperfusion (* $P < 0.05$; ** $P < 0.01$).

creased in both groups (controls: 1.69 ± 0.19 ; versus LPS: 1.11 ± 0.17 mg/dl). However, this increase was more pronounced in controls. Thereafter creatinine remained constant in the LPS group (1.21 ± 0.16 mg/dl), whereas it increased in controls (3.03 ± 0.18 mg/dl). One hour after ischemia, the differences between the groups reached statistical significance (Figure 2).

Histology and Immunohistochemistry

Immediately before ischemia, minor tubular damage was observed in the LPS group, although kidneys from controls had no apparent morphological changes. At 15 minutes after reperfusion, tubular damage was similar in LPS- and vehicle-treated animals. However, the damage progressed slowly in LPS-pretreated animals up to 2 hours after reperfusion and returned to a normal appearance after 8 hours. The degree of leukocyte infiltration was low in these animals. Kidneys of vehicle-treated animals deteriorated dramatically over time with an accompanying strong infiltration of leukocytes. The infiltrate consisted predominantly of neutrophils. By 8 hours after reperfusion, almost half of the kidney was destroyed in these animals (Table 2 and Figure 3). Furthermore, we

Figure 3. Effect of LPS pretreatment on kidney damage before ("0") and 15 minutes, 1, 2, 8, and 16 hours after lethal renal ischemia (** $P < 0.01$).

observed more cells undergoing apoptosis in controls than in LPS-pretreated animals. As revealed by the TUNEL assay, 1.80 ± 0.64 cells per field of view stained positive in LPS-pretreated animals compared with 0.53 ± 0.17 in controls at 16 h after ischemia ($P < 0.01$).

RT-PCR

At 2 hours, the expression of TNF- α mRNA was significantly higher in the LPS group than in controls. Furthermore, in LPS-treated animals, macrophage-associated IL-6 mRNA levels were threefold lower before ischemia than in controls and remained significantly lower at 15 minutes after reperfusion, but these levels increased to higher levels than in controls thereafter. On the other hand, in both groups, IL-1 was up-regulated at 15 minutes, low until 2 hours, and up-regulated at 8 and 16 hours. The mRNA patterns of IFN- γ , IL-1, and iNOS did not differ between the groups (Figure 5).

Discussion

Tissue adaptation to repeated stress has long been described. However, the observation that cells can acutely adapt to an insult and then revert back to a resting or

Table 2. Quantification of Kidney Damage Before and After Ischemia/Reperfusion Injury

Time (h)	Groups	Criteria							
		Leukocyte infiltration	Nucleus atypia	Vacuolization in the tubular cells	Hyalinization in the tubular cells	Dissolve of the tubular cells	Coming off of the tubular cells	Lack of the tubular cells	Hyaline in the tubules
0	Controls	0.0 ± 0.0	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
	LPS	0.0 ± 0.0	0.58 ± 0.20	0.14 ± 0.14	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.14 ± 0.14
0.25	Controls	0.5 ± 0.15	0.40 ± 0.16	0.10 ± 0.01	0.00 ± 0.00	0.00 ± 0.00	0.60 ± 0.16	0.10 ± 0.01	0.00 ± 0.00
	LPS	0.3 ± 0.15	0.88 ± 0.22	0.50 ± 0.19	0.25 ± 0.16	0.00 ± 0.00	0.88 ± 0.12	0.13 ± 0.14	0.38 ± 0.18
1	Controls	1.1 ± 0.26**	1.13 ± 0.10	0.50 ± 0.19	0.50 ± 0.19	0.13 ± 0.12	1.13 ± 0.12	1.00 ± 0.18	0.13 ± 0.12
	LPS	0.6 ± 0.15	1.00 ± 0.24	0.66 ± 0.24	0.44 ± 0.17	0.33 ± 0.24	0.77 ± 0.22	0.33 ± 0.24	0.22 ± 0.22
2	Controls	0.8 ± 0.14**	1.6 ± 0.24	1.00 ± 0.32	0.80 ± 0.20	0.80 ± 0.20	1.60 ± 0.24	0.80 ± 0.20	0.80 ± 0.20
	LPS	0.2 ± 0.15	1.00 ± 0.00	0.75 ± 0.25	0.50 ± 0.29	0.00 ± 0.00	1.00 ± 0.00	0.50 ± 0.29	0.75 ± 0.25
8	Controls	1.4 ± 0.2**	2.22 ± 0.15**	1.67 ± 0.17**	1.22 ± 0.15*	1.78 ± 0.15**	2.11 ± 0.20**	1.67 ± 0.17**	1.67 ± 0.24*
	LPS	0.3 ± 0.15	0.67 ± 0.16	0.44 ± 0.17	0.78 ± 0.13	0.22 ± 0.13	0.89 ± 0.20	0.44 ± 0.17	0.78 ± 0.22
16	Controls	1.2 ± 0.2**	2.44 ± 0.17**	2.00 ± 0.16**	1.33 ± 0.16**	1.78 ± 0.15**	2.44 ± 0.17**	1.78 ± 0.15**	2.11 ± 0.26**
	LPS	0.3 ± 0.15	1.00 ± 0.17	0.78 ± 0.22	0.22 ± 0.13	0.22 ± 0.13	0.89 ± 0.11	0.22 ± 0.13	0.56 ± 0.24

* $P < 0.05$; ** $P < 0.01$.

Figure 4. Effect of LPS pretreatment on infiltration of the kidney with CD4⁺ lymphocytes (**a**) and neutrophils (**b**) before ("0") and 15 minutes, 1, 2, 8, and 16 hours after lethal renal ischemia (* $P < 0.05$). Cells were counted at $\times 400$ magnification and expressed as cells per field of view.

steady-state phenotype has only recently been elucidated. One of the first descriptions of acute adaptation was reported in HeLa cells,¹⁸ in which sublethal hyperthermic stress conferred tolerance to a subsequent hyperthermic insult. Conditioning the cells against thermal insult does not only seem to be conserved across many cell types but may also induce cross-tolerance to other forms of injury. In this study, we demonstrated for the first time that repeated LPS pretreatment protected mice from otherwise lethal renal ischemia/reperfusion injury. Brown et al¹⁰ and Colletti et al¹⁵ have previously reported that endotoxins protect from myocardial and hepatic ischemia/reperfusion. However, they did not analyze cytotoxic patterns, nor did they study a similar model of ischemia/reperfusion injury.

Despite experiments, the underlying mechanisms and cellular mediators responsible for the endotoxin-related tolerance to ischemia/reperfusion injury remain elusive. It is known that polymorphonuclear cells are involved in this process. The results of *in vitro* and *in vivo* experiments have supported the conclusion that macrophage-associated cytokines, such as TNF- α , IL-1, IL-6, and IFN- γ , may play a major role in this process.¹⁹ The most widely examined cytokine in the development of endotoxin tolerance is TNF- α . We demonstrated an increased level of TNF- α mRNA expression after renal ischemia in LPS-pretreated animals. However, despite an increased TNF- α mRNA level, renal injury was reduced. These results indicate an involvement of TNF- α and particularly a missing response to TNF- α . It is known that TNF- α appears almost immediately on LPS injection in mice. However, repeated injections of LPS resulted in unresponsiveness, and no further TNF- α production was detectable for at least days.⁷ In contrast to our experiment, these results indicated a direct involvement to TNF- α because the level of TNF- α correlated to LPS unresponsiveness.

However, the TNF- α level also increased in another experiment after endotoxin pretreatment and hepatic ischemia/reperfusion injury, and again this elevation correlated to a protection against lung injury after hepatic

Figure 5. Effect of LPS pretreatment on the kinetics of cytokine gene expression in the injured kidney. **A:** TNF- α ; **B:** IL-6; **C:** IL-1; **D:** IFN- γ ; **E:** iNOS. ■, LPS group; □, controls; * $P < 0.05$.

reperfusion.¹⁵ The mechanism for the enhanced production of TNF- α in animals treated with LPS and subsequently subjected to ischemia is difficult to explain. The most likely hypothesis for the protective effects induced by nonlethal LPS administration is a transient induction of TNF- α . This early increase of TNF- α will then provide protection against the subsequent organ damage by a down-regulation of TNF receptors.²⁰ Otherwise it is hard to explain why the damages were reduced by LPS pretreatment despite a higher TNF- α mRNA expression.

In parallel to these results, we were not able to detect any differences in the kinetics of IL-1 and IFN- γ mRNA expression between the groups. However, the level of IL-6 mRNA was significantly reduced before ischemia and shortly after reperfusion in LPS-pretreated animals. In an *in vivo* study, Hewitt et al demonstrated that intermittent ischemia (preconditioning) resulted in significantly decreased IL-6 and TNF- α expression as compared with continuous ischemia (without conditioning).²² In addition, it has been reported that daily injections of LPS in rats resulted in a measurable release of TNF- α and IL-6 within the first few days only and was abrogated thereafter.²² Our data indicate that repeated treatment of endotoxin can inhibit IL-6 mRNA expression in the injured organ. We think that reduced IL-6 expression may reflect a state of unresponsiveness of macrophages. This may be related to down-regulation of the TNF receptors. On the other hand, IL-6 by itself is a strong chemoattractant and may lead to the infiltration and consequential activation of leukocytes. This hypothesis would explain the reduced infiltration observed in the LPS group. The reduced infiltration by these leukocytes could further explain the lower degree of damage and apoptosis in these animals.

However, another hypothesis can be postulated. Hypoxia is one of the most pronounced promoters of necrosis/apoptosis by itself. As a result of necrosis/apoptosis, leukocytes infiltrate to phagocytose the damaged tissue. If LPS pretreatment reduces the susceptibility of tissue cells to hypoxia-induced cell death *per se*, the degree of damaged tissue would be reduced, and fewer leukocytes would infiltrate the affected organs.

Cytokines induce *i*NOS gene expression²³ and thus increase NO levels. After ischemia and reperfusion, injured vascular cells and adherent leukocytes produce free radicals and inactivate NO, which may promote vasoconstriction and increase permeability, local edema, and leukocyte adhesion. Because we did not find any differences in *i*NOS mRNA expression between our groups, we would conclude that NOS is of minor importance for ischemia/reperfusion in our model. However, we examined mRNA expression of cytokines only in organs and not in the blood or specifically in the endothelium. Thus, it is possible that differences related to certain cells, eg, endothelial cells, were not detected. Additionally, we used RT-PCR to detect the mRNA levels of cytokines, while others examined the protein level in the blood or, for endotoxin tolerance, in the peritoneal macrophages. Whole-blood assays are certainly reasonable in septicemia, but, based on the short half-life of the mediators involved, these assays seem to poorly reflect processes in a single organ such as the kidney. Therefore

we did not perform such assays. Furthermore, although peritoneal macrophages are undoubtedly a good model for LPS-tolerance, their function and relation to renal injury are unknown and hard to predict. Additionally, most experiments were performed *in vitro* and not *in vivo*.

How LPS pretreatment confers protection against renal ischemia/reperfusion injury remained unclear but is undoubtedly multifactorial. Early investigators believed that low-dose LPS stimulates the reticulo-endothelial system such that subsequent larger doses of LPS are more actively cleared.²⁴ More recently, the predominant mechanism emphasized is that low-dose LPS alters monocyte secretion of a variety of inflammatory mediators including proteolytic enzymes, arachidonic acid metabolites, reactive oxygen species, and cytokines.^{25–30} On the other hand, low-dose LPS could directly down-regulate the expression of endothelial-cell adhesion receptors, which could account for the decrease in tissue sequestration of neutrophils.³¹ Key molecules involved in this endothelial cell-neutrophil adhesion are intracellular adhesion molecule-1³² and E-selectin.^{33,34} Both are an ideal molecular indicator of endothelial cell activation in response to ischemia/reperfusion injury. In *in vitro* models, hypoxia/reoxygenation stimulated endothelial cells to express adhesion molecules and increased adhesion of neutrophils to the endothelial surface.³⁵ Neutrophil depletion has been shown to protect rats against ischemic renal injury in some studies.^{36,37} Thus, given the complexity of events preceding neutrophil invasion into the tissues, one could postulate that LPS pretreatment may inhibit the activation of endothelial cells.

Although renal failure after ischemia and reperfusion can be managed by dialysis, such injury influences the outcome of transplantation, revascularization procedures, and episodes of hypoperfusion. In this experiment we developed a new model for endotoxin-induced cross-tolerance to renal ischemia/reperfusion injury. Although this model may seem quite extreme, similar damages may occur in the clinical setting for non-heart-beating donors. TNF- α and IL-6 may play a central role in this process. However, future studies are needed to decipher the exact causes of the increased survival in this model.

References

1. Forman MB, Virmani R, Peutt DW: Mechanism and therapy of myocardial reperfusion injury. *Circulation* 1990, 81(Suppl 4):69–78
2. Cafe C, Torri C, Marzatico F: Cellular and molecular events of ischemic brain damage. *Funct Neurol* 1993, 8:121–133
3. Paller MS: Effect of neutrophil depletion on ischemic renal injury in the rat. *J Lab Clin Med* 1989, 113:379–386
4. Park PO, Haglund U, Bulkley GB, Falt K: The sequence of development of intestinal tissue injury after strangulation ischemia and reperfusion. *Surgery* 1990, 107:574–580
5. Alkhunaizi AM, Schrier RW: Management of acute renal failure: new perspectives. *Am J Kidney Dis* 1996, 28:315–328
6. Bonventre JV: Mechanisms of ischemic acute renal failure. *Kidney Int* 1993, 43:1160–1178
7. Szabo A, Heemann U: Ischemia/reperfusion injury, and chronic allograft rejection: *Transplant Proc* 1998, 30:4281–4284
8. Woolfson RG, Millar CGM, Neild GH: Ischemia and reperfusion injury in the kidney: current status and future direction. *Nephrol Dial Transplant* 1994, Editorial Comments:1529–1531

9. Ayala A, Kisala JM, Perrin MM, Chaudry IH: Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin-1, interleukin-6, or tumor necrosis factor) during sepsis? *Arch Surg* 1992; 127:191-197
10. Brown JM, Grosso MA, Terada LS, Whitman GJR, Banerjee A, White CW, Harken AH, Repine JE: Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. *Proc Natl Acad Sci USA* 1989; 86:2516-2520
11. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH: Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators. *Circ Shock* 1992; 36:191-199
12. Ayala A, Ertel W, Chaudry IH: Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. *Shock* 1996; 5:79-90
13. Meng X, Brown JM, Ao L, Nordeen SK, Franklin W, Harken AH, Banerjee A: Endotoxin induces cardiac HSP70 and resistance to endotoxemic myocardial depression in rats. *Am J Physiol* 1996; 271: 1316-1324
14. Meldrum DR, Sheridan BC, Cleveland JC Jr, Fullerton DA, Banerjee A, Harken AH: Neutrophils are required for endotoxin-induced myocardial cross-tolerance to ischemia-reperfusion injury. *Arch Surg* 1996; 131:1203-1208
15. Colletti LM, Remick DG, Campbell DA Jr: LPS pretreatment protects from hepatic ischemia/reperfusion. *J Surg Res* 1994; 57:337-343
16. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Ann Biochem* 1987; 162:156-161
17. Platzer C, Ode-Hakim S, Döcke WD, Ewert R, Volk HD: Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multi-specific competitor fragments. *Transplantation* 1994; 58:264-268
18. Gerner EW, Schneider MJ: Induced thermal resistance in HeLa cells. *Nature* 1975; 256:500-502
19. Vogel SN, Hogan MM: The role of cytokines in endotoxin mediated responses. *Immunophysiology: Role of Cells and Cytokines in Immunity and Inflammation*. Edited by JJ Openheim, E Shevach. New York: Oxford Univ. Press, 1987
20. Sheppard BC, Fraker DL, Norton JA: Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. *Surgery* 1989; 106:156-160
21. Beutler B, Milsark IW, Cerami A: Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effects of endotoxin. *Science* 1985; 229:869-871
22. Hewitt G, Halliday M, McCaigue M, Campbell G, Rowlands B, Diamond T: Mortality, endotoxemia, and cytokine expression after intermittent, and continuous hepatic ischemia. *Br J Surg* 1995; 82:1424-1426
23. He W, Fong Y, Marano MA, Gershenwald JE, Yurt RW, Moldawer LL, Lowry SF: Tolerance to endotoxin prevents mortality in infected thermal injury: association with attenuated cytokine response. *J Infect Dis* 1992; 165:859-864
24. Li MH, Seatter SC, Manthei R, Bubrick M, West MA: Macrophage endotoxin tolerance: effect of TNF or endotoxin pretreatment. *J Surg Res* 1994; 57:85-92
25. Liu S, Adcock IM, Old RW, Barnes PJ, Evans TW: Lipopolysaccharide treatment in vivo induces widespread tissue expression of inducible nitric oxide synthase mRNA. *Biochem Biophys Res Commun* 1993; 3:1208-1213
26. Zweifach BW: Relation of the reticulo-endothelial system to natural and acquired resistance in shock. *Int Anesth Clin* 1964; 2:271
27. Strieter RM, Lynch JP III, Basha MA, Standiford TJ, Kasahara K, Kunkle SL: Host responses in mediating sepsis and the adult respiratory distress syndrome. *Semin Respir Infect* 1990; 5:233-247
28. Schlag G, Redl H, Hallstrom S: The cell in shock: the origin of multiple organ failure. *Resuscitation* 1991; 21:137-180
29. Flick MR, Perel A, Staub NC: Leukocytes are required for increased lung microvascular permeability after microembolization in sheep. *Circ Res* 1981; 48:344-348
30. Weiss SJ, Regiani S: Neutrophils degrade subendothelial matrices in the presence of α -1-protease inhibitor: cooperative use of lysosomal proteases and oxygen metabolites. *J Clin Invest* 1984; 73:1297-1304
31. Baird BR, Cheronis JC, Sandhaus RA, Berger EM, White CW, Repine JE: O metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. *J Appl Physiol* 1986; 61:2224-2229
32. Koike K, Moore FA, Moore EE, Trew CE, Banerjee A, Peterson VM: Endotoxin pretreatment inhibits neutrophil proliferation and function. *J Surg Res* 1994; 57:49-54
33. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutiérrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. *J Clin Invest* 1996; 4:1056-1063
34. Pober JS, Cotran RS: The role of endothelial cells in inflammation. *Transplantation* 1990; 50:537-544
35. Billups KL, Palladino MA, Hinton BT, Sherley JL: Expression of E-selectin mRNA during ischemia/reperfusion injury. *J Lab Clin Med* 1995; 5:626-633
36. Palluy O, Morliere L, Gris JC, Bonne C, Modat G: Hypoxia/reoxygenation stimulates endothelium to promote neutrophil adhesion: Free Radic Biol Med 1992; 13:21-30
37. Hellberg POA, Kallskog OT, Ojteg G, Wolgast M: Peritubular capillary permeability and intravascular RBC aggregation after ischemia: effects of neutrophils. *Am J Physiol* 1990; 258:F1018-1025
38. Klausner JM, Paterson IS, Goldman G, Kobzik L, Rodzen C, Lawrence R, Valeri CR, Shepro D, Hechtman HB: Postischemic renal injury is mediated by neutrophils and leukotrienes. *Am J Physiol* 1989; 256:794-802